News Ipsen

Stocks

IPN

FR0010259150

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-08-04 EDT			After hours 16:00:00
156.90 ^EUR	+2.48%		157.40	+0.32%

08-03	Jefferies Downgrades Ipsen to Underperform, Boosts PT	MT
08-03	Middle East hopes lift Europe into the green

All News

Mentions Relevance

08-03	IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2026	GL
08-03	Jefferies Downgrades Ipsen to Underperform, Boosts PT	MT
07-31	Ipsen S.A., H1 2026 Earnings Call, Jul 30, 2026
07-30	Ipsen S.A. publishes its 2026 Half-Year Report (half-year ended 30 June 2026)	GL
07-30	Ipsen: Another quarterly beat; 2026 guidance upgraded
07-30	Ipsen S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-30	Ipsen raises its full-year targets
07-30	Ipsen Raises FY26 Sales Growth Outlook	MT
07-30	Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance	GL
07-29	Ipsen nominates Catherine Bradley to its Board of Directors as independent Director	GL
07-29	Ipsen Announces Appointment of Catherine Bradley, CBE, as an Independent Director, Chair of the Audit Committee and Member of the Compensation Committee, Effective July 29, 2026	CI
07-27	IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2026	GL
07-24	Ipsen Provides Update On Phase III BOLD Trial In Biliary Atresia	CI
07-24	Ipsen Says Phase 3 Trial of Bylvay in Biliary Atresia Misses Primary Endpoint	MT
07-24	Ipsen provides update on Phase III BOLD trial in biliary atresia	GL
07-22	Ipsen Closes Purchase of Potravitug Developer Memo Therapeutics	MT
07-22	Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline	GL
07-21	Ipsen S.A. acquired Memo Therapeutics AG.	CI
07-21	IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2026	GL
07-15	IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2026	GL
07-13	Positive news for Ipsen's Iqirvo
07-13	Ipsen : IQIRVO® demonstrates statistically significant improvement in ALP normalization in patients with PBC in Phase IIIb ELSPIRE study	PU
07-10	Ipsen - Dysport is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine	AQ
07-09	Ipsen Reports Positive Topline Phase III Results for Dysport in Both Episodic and Chronic Migraine	CI
07-09	Ipsen's Migraine Treatment Meets Primary Endpoints in Late-stage Trial	MT